Free Trial
NASDAQ:AVXL

Anavex Life Sciences (AVXL) Stock Price, News & Analysis

Anavex Life Sciences logo
$11.19 +0.43 (+3.99%)
As of 03:01 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About Anavex Life Sciences Stock (NASDAQ:AVXL)

Key Stats

Today's Range
$10.64
$11.11
50-Day Range
$7.37
$10.76
52-Week Range
$4.52
$14.44
Volume
689,635 shs
Average Volume
1.19 million shs
Market Capitalization
$955.20 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$44.00
Consensus Rating
Buy

Company Overview

Anavex Life Sciences Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
72nd Percentile Overall Score

AVXL MarketRank™: 

Anavex Life Sciences scored higher than 72% of companies evaluated by MarketBeat, and ranked 272nd out of 920 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Anavex Life Sciences has received a consensus rating of Buy. The company's average rating score is 3.33, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Anavex Life Sciences has received no research coverage in the past 90 days.

  • Read more about Anavex Life Sciences' stock forecast and price target.
  • Earnings Growth

    Earnings for Anavex Life Sciences are expected to grow in the coming year, from ($0.69) to ($0.66) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Anavex Life Sciences is -20.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Anavex Life Sciences is -20.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Anavex Life Sciences has a P/B Ratio of 7.85. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Anavex Life Sciences' valuation and earnings.
  • Percentage of Shares Shorted

    33.33% of the float of Anavex Life Sciences has been sold short.
  • Short Interest Ratio / Days to Cover

    Anavex Life Sciences has a short interest ratio ("days to cover") of 26.6, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Anavex Life Sciences has recently increased by 0.72%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    Anavex Life Sciences does not currently pay a dividend.

  • Dividend Growth

    Anavex Life Sciences does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    33.33% of the float of Anavex Life Sciences has been sold short.
  • Short Interest Ratio / Days to Cover

    Anavex Life Sciences has a short interest ratio ("days to cover") of 26.6, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Anavex Life Sciences has recently increased by 0.72%, indicating that investor sentiment is decreasing.
  • News Sentiment

    Anavex Life Sciences has a news sentiment score of 0.45. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.56 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 2 news articles for Anavex Life Sciences this week, compared to 4 articles on an average week.
  • Search Interest

    Only 18 people have searched for AVXL on MarketBeat in the last 30 days. This is a decrease of -36% compared to the previous 30 days.
  • MarketBeat Follows

    Only 6 people have added Anavex Life Sciences to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Anavex Life Sciences insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    11.40% of the stock of Anavex Life Sciences is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Only 31.55% of the stock of Anavex Life Sciences is held by institutions.

  • Read more about Anavex Life Sciences' insider trading history.
Receive AVXL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Anavex Life Sciences and its competitors with MarketBeat's FREE daily newsletter.

AVXL Stock News Headlines

$100 Trillion “AI Metal” Found in American Ghost Town
Jeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could be the biggest technology story of this decade. In short, he believes what he's holding in his hand is the key to the $100 trillion AI boom… And only one company here in the U.S. can mine this obscure metal.
See More Headlines

AVXL Stock Analysis - Frequently Asked Questions

Anavex Life Sciences' stock was trading at $10.74 at the beginning of the year. Since then, AVXL stock has increased by 3.8% and is now trading at $11.1490.

Anavex Life Sciences Corp. (NASDAQ:AVXL) announced its quarterly earnings results on Tuesday, May, 13th. The biotechnology company reported ($0.13) EPS for the quarter, topping analysts' consensus estimates of ($0.16) by $0.03.
Read the conference call transcript
.

Top institutional shareholders of Anavex Life Sciences include Wealth Enhancement Advisory Services LLC (0.02%). Insiders that own company stock include Christopher U Missling, Steffen Thomas and Peter DO Donhauser.
View institutional ownership trends
.

Shares of AVXL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Anavex Life Sciences investors own include Symbotic (SYM), JPMorgan Nasdaq Equity Premium Income ETF (JEPQ), Mesa Air Group (MESA), Innovative Industrial Properties (IIPR), Voya Infrastructure, Industrials and Materials Fund (IDE), Meta Platforms (META) and NVIDIA (NVDA).

Company Calendar

Last Earnings
5/13/2025
Today
7/10/2025
Next Earnings (Estimated)
8/05/2025
Fiscal Year End
9/30/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:AVXL
CIK
1314052
Fax
N/A
Employees
40
Year Founded
N/A

Price Target and Rating

High Price Target
$46.00
Low Price Target
$42.00
Potential Upside/Downside
+298.6%
Consensus Rating
Buy
Rating Score (0-4)
3.33
Research Coverage
3 Analysts

Profitability

EPS (Trailing Twelve Months)
($0.55)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$43 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-40.93%
Return on Assets
-36.38%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
6.74
Quick Ratio
6.74

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$1.42 per share
Price / Book
7.77

Miscellaneous

Outstanding Shares
85,370,000
Free Float
75,640,000
Market Cap
$942.48 million
Optionable
Optionable
Beta
0.72

Social Links

The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

This page (NASDAQ:AVXL) was last updated on 7/10/2025 by MarketBeat.com Staff
From Our Partners